Advertisement

Topics

Merck: KEYTRUDA-pemetrexed-platinum Chemotherapy Combination Improved OS

10:10 EDT 16 Apr 2018 | FinanzNachrichten

KENILWORTH (NJ) (dpa-AFX) - Merck (MRK) announced results from KEYNOTE-189, a pivotal Phase 3 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, in combination with pemetrexed or ALIMTA and cis...

Original Article: Merck: KEYTRUDA-pemetrexed-platinum Chemotherapy Combination Improved OS

NEXT ARTICLE

More From BioPortfolio on "Merck: KEYTRUDA-pemetrexed-platinum Chemotherapy Combination Improved OS"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...